EX-99.2O OTH FIN ST 4 exhibi99204q2010.htm exhibi99204q2010.htm
Exhibit 99.2O
 
Johnson & Johnson and Subsidiaries
                    
Condensed Consolidated Statement of Earnings
                
   
 
  
 
 
 
  
 
    
(Unaudited; in Millions Except Per Share Figures)
FOURTH QUARTER
   
2009
  
2008
  
Percent
       
Percent
      
Percent
  
Increase
   
Amount
  
to Sales
 
Amount
  
to Sales
  
(Decrease)
Sales to customers
  
 $         16,551
  
100.0
  
 $         15,182
  
100.0
  
9.0
Cost of products sold
  
             5,312
  
32.1
  
             4,372
  
28.8
  
21.5
Selling, marketing and administrative expenses
  
5,629
  
34.0
  
5,665
  
37.3
  
(0.6)
Research expense
  
2,213
  
13.4
  
2,108
  
13.9
  
5.0
In-process research & development (IPR&D)
  
                    -
  
                   -
  
                141
  
0.9
    
Interest (income)expense, net
  
81
  
0.5
  
17
  
0.1
    
Other (income)expense, net
  
(361)
  
(2.2)
  
(638)
  
(4.2)
    
Restructuring expense
  
             1,073
  
6.5
  
                    -
  
                    -
    
Earnings before provision for taxes on income
  
2,604
  
15.7
  
3,517
  
23.2
  
(26.0)
Provision for taxes on income
  
398
  
2.4
  
803
  
5.3
  
(50.4)
Net earnings
  
 $           2,206
  
13.3
  
 $           2,714
  
17.9
  
(18.7)
                     
Net earnings per share  (Diluted)
  
 $             0.79
      
 $             0.97
      
(18.6)
                     
Average shares outstanding  (Diluted)
  
2,796.5
      
2,801.6
        
                     
Effective tax rate
  
15.3
%
    
22.8
%
    
 
                     
Adjusted earnings before provision for taxes and net earnings (A)
              
     Earnings before provision for taxes on income
 $           3,404
 (1)
20.6
  
 $           3,279
 (2)
21.6
  
3.8
     Net earnings
  
 $           2,846
 (1)
17.2
  
 $           2,626
 (2)
17.3
  
8.4
     Net earnings per share  (Diluted)
  
 $             1.02
 (1)
    
 $             0.94
 (2)
    
8.5
     Effective tax rate
  
16.4
 %     
19.9
 %       
                     
 
(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of $1,186 million ($1,073 million restructuring expense and $113 million related to restructuring included in cost of products sold), $852 million and $0.31 per share, respectively, and the exclusion of income from net litigation of $386 million, $212 million and $0.08 per share, respectively.
                       
(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of $141 million with no tax benefit and $0.05 per share, respectively, and the exclusion of income from net litigation of $379 million, $229 million and $0.08 per share, respectively.
                       
 

 
 
 

Johnson & Johnson and Subsidiaries
                    
Condensed Consolidated Statement of Earnings
                    
         
 
 
 
 
  
 
(Unaudited; in Millions Except Per Share Figures)
  
TWELVE MONTHS
   
2009
  
2008
  
Percent
       
Percent
      
Percent
  
Increase
   
Amount
  
to Sales
  
Amount
  
to Sales
  
(Decrease)
Sales to customers
  
 $         61,897
  
100.0
  
 $         63,747
  
100.0
  
(2.9)
Cost of products sold
  
18,447
  
29.8
  
18,511
  
29.1
  
(0.3)
Selling, marketing and administrative expenses
  
19,801
  
32.0
  
21,490
  
33.7
  
(7.9)
Research expense
  
6,986
  
11.3
  
7,577
  
11.9
  
(7.8)
In-process research & development (IPR&D)
  
                    -
  
                   -
  
181
  
0.3
    
Interest (income)expense, net
  
361
  
0.6
  
74
  
0.1
    
Other (income)expense, net
  
(526)
  
(0.8)
  
(1,015)
  
(1.6)
  
 
Restructuring expense
  
             1,073
  
1.7
  
                    -
  
-
    
Earnings before provision for taxes on income
  
15,755
  
25.4
  
16,929
  
26.5
  
(6.9)
Provision for taxes on income
  
             3,489
  
5.6
  
             3,980
  
6.2
  
(12.3)
Net earnings
  
 $         12,266
  
19.8
  
 $         12,949
  
20.3
  
(5.3)
                     
Net earnings per share  (Diluted)
  
 $             4.40
      
 $             4.57
      
(3.7)
                     
Average shares outstanding  (Diluted)
  
2,789.1
      
2,835.6
        
                     
Effective tax rate
  
22.1
%
    
23.5
%
    
 
                     
Adjusted earnings before provision for taxes and net earnings (A)
                
     Earnings before provision for taxes on income
 $         16,555
 (1)
26.7
  
 $         16,731
 (2)
26.2
  
(1.1)
     Net earnings
  
 $         12,906
 (1)
20.9
  
 $         12,901
 (2)
20.2
  
-
     Net earnings per share  (Diluted)
  
 $             4.63
 (1)
    
 $             4.55
 (2)
    
1.8
     Effective tax rate
  
22.0
 %    
22.9
  %       

(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of $1,186 million ($1,073 million restructuring expense and $113 million related to restructuring included in cost of products sold), $852 million and $0.31 per share, respectively, and the exclusion of income from fourth quarter net litigation of $386 million, $212 million and $0.08 per share, respectively.

(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of IPR&D of $181 million with no tax benefit and $0.06 per share, respectively, and the exclusion of income from fourth quarter net litigation of $379 million, $229 million and $0.08 per share, respectively.
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, they may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as business development activities (including IPR&D at acquisition or upon attainment of milestones and any extraordinary expenses), strategic developments (including restructuring and product line changes), significant litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, merger-related or other restructuring charges, or amortization of purchased intangibles, and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.
 
 
 

Johnson & Johnson and Subsidiaries
                
Supplementary Sales Data
                  
                   
(Unaudited; Dollars in Millions)
FOURTH QUARTER*
         
Percent Change
 
2009
  
2008
  
Total
   Operations
Currency
Sales to customers by
                  
segment of business
                  
                   
Consumer
                  
    U.S.
 $  1,712
  
   1,655
  
   3.4
%
          3.4
  
            -
    International
     2,537
  
   2,200
  
 15.3
  
          6.5
  
        8.8
 
     4,249
 
   3,855
  
 10.2
  
          5.2
  
        5.0
                   
Pharmaceutical
                  
    U.S.
     3,338
  
   3,430
  
  (2.7)
  
         (2.7)
  
            -
    International
     2,655
  
   2,255
  
 17.7
  
          8.0
  
        9.7
 
     5,993
 
   5,685
  
   5.4
  
          1.6
  
        3.8
                   
Med Devices & Diagnostics
                  
    U.S.
     2,817
 
   2,582
  
   9.1
  
          9.1
  
            -
    International
     3,492
  
   3,060
  
 14.1
  
          4.9
  
        9.2
 
     6,309
 
   5,642
  
 11.8
  
          6.8
  
        5.0
                   
U.S.
     7,867
  
   7,667
  
   2.6
  
          2.6
  
            -
International
     8,684
  
   7,515
  
 15.6
  
          6.4
  
        9.2
Worldwide
 $16,551
  
 15,182
  
   9.0
%
          4.5
  
        4.5
                   
*Fourth Quarter 2009 includes fourteen weeks and 2008 includes thirteen weeks.
    
                   

 
 
 

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
                  
                   
(Unaudited; Dollars in Millions)
TWELVE MONTHS**
         
Percent Change
 
2009
  
2008
  
Total
   Operations
Currency
Sales to customers by
                  
segment of business
                  
                   
Consumer
                  
    U.S.
 $  6,837
  
   6,937
  
   (1.4)
%
         (1.4)
  
            -
    International
     8,966
  
   9,117
  
   (1.7)
  
          4.7
  
       (6.4)
 
   15,803
 
 16,054
  
   (1.6)
  
          2.0
  
       (3.6)
                   
Pharmaceutical
                  
    U.S.
   13,041
  
 14,831
  
 (12.1)
  
       (12.1)
  
            -
    International
     9,479
  
   9,736
  
   (2.6)
  
          3.0
  
       (5.6)
 
   22,520
 
 24,567
  
   (8.3)
  
         (6.1)
  
       (2.2)
                   
Med Devices & Diagnostics
                  
    U.S.
   11,011
 
 10,541
  
    4.5
  
          4.5
  
            -
    International
   12,563
  
 12,585
  
   (0.2)
  
          4.0
  
       (4.2)
 
   23,574
 
 23,126
  
    1.9
  
          4.2
  
       (2.3)
                   
U.S.
   30,889
  
 32,309
  
   (4.4)
  
         (4.4)
  
            -
International
   31,008
  
 31,438
  
   (1.4)
  
          3.9
  
       (5.3)
Worldwide
 $61,897
  
 63,747
  
   (2.9)
%
         (0.3)
  
       (2.6)
                   
**Twelve Months 2009 includes fifty-three weeks and 2008 includes fifty-two weeks.
 

 
 
 

Johnson & Johnson and Subsidiaries
                
Supplementary Sales Data
                  
                   
(Unaudited; Dollars in Millions)
FOURTH QUARTER*
         
Percent Change
 
2009
  
2008
  
Total
   Operations
Currency
Sales to customers by
                  
geographic area
                  
                   
U.S.
 $    7,867
  
     7,667
  
   2.6
%
          2.6
  
            -
                   
Europe
       4,412
  
     3,851
  
 14.6
  
          5.1
  
        9.5
Western Hemisphere excluding U.S.
       1,541
  
     1,187
  
 29.8
  
        19.0
  
      10.8
Asia-Pacific, Africa
       2,731
  
     2,477
  
 10.3
  
          2.3
  
        8.0
International
       8,684
  
     7,515
  
 15.6
  
          6.4
  
        9.2
 
 
  
 
  
 
  
 
  
 
Worldwide
 $  16,551
  
   15,182
  
   9.0
%
          4.5
  
        4.5
                   
*Fourth Quarter 2009 includes fourteen weeks and 2008 includes thirteen weeks.
    
 

 
 
 

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
                  
                   
(Unaudited; Dollars in Millions)
TWELVE MONTHS**
         
Percent Change
 
2009
  
2008
  
Total
   Operations
Currency
Sales to customers by
                  
geographic area
                  
                   
U.S.
 $  30,889
  
   32,309
  
 (4.4)
%
         (4.4)
  
            -
                   
Europe
     15,934
  
   16,782
  
 (5.1)
  
          2.1
  
       (7.2)
Western Hemisphere excluding U.S.
       5,156
  
     5,173
  
 (0.3)
  
          8.8
  
       (9.1)
Asia-Pacific, Africa
       9,918
  
     9,483
  
  4.6
  
          4.4
  
        0.2
International
     31,008
  
   31,438
  
 (1.4)
  
          3.9
  
       (5.3)
 
 
  
 
  
 
  
 
  
 
Worldwide
 $  61,897
  
   63,747
  
 (2.9)
%
         (0.3)
  
       (2.6)
                   
**Twelve Months 2009 includes fifty-three weeks and 2008 includes fifty-two weeks.
 
 


 
 
 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
CONSUMER SEGMENT (2)
            
                   
SKIN CARE
                
US
        
       378
      343
10.2%
10.2%
             -
Intl
        
       572
      501
14.2%
6.7%
7.5%
WW
        
       950
      844
12.6%
8.1%
4.5%
         
 
 
      
BABY CARE
                
US
        
       106
      109
(2.8%)
(2.8%)
             -
Intl
        
       468
      414
13.0%
5.0%
8.0%
WW
        
       574
      523
9.8%
3.4%
6.4%
         
 
 
      
ORAL CARE
                
US
        
       167
      192
(13.0%)
(13.0%)
             -
Intl
        
       241
      204
18.1%
9.1%
9.0%
WW
        
       408
      396
3.0%
(1.7%)
4.7%
         
 
 
      
OTC/NUTRITIONALS
              
US
        
       807
      762
5.9%
5.9%
             -
Intl
        
       767
      694
10.5%
2.2%
8.3%
WW
        
    1,574
   1,456
8.1%
4.2%
3.9%
         
 
 
      
WOMEN'S HEALTH
              
US
        
       135
      148
(8.8%)
(8.8%)
             -
Intl
        
       354
      288
22.9%
12.4%
10.5%
WW
        
       489
      436
12.2%
5.2%
7.0%
         
 
 
      
WOUND CARE / OTHER
            
US
        
       119
      101
17.8%
17.8%
             -
Intl
        
       135
        99
36.4%
20.2%
16.2%
WW
        
       254
      200
27.0%
20.0%
7.0%
         
 
 
      
TOTAL CONSUMER
              
US
        
    1,712
   1,655
3.4%
3.4%
             -
Intl
        
    2,537
   2,200
15.3%
6.5%
8.8%
WW
        
    4,249
   3,855
10.2%
5.2%
5.0%
 
Note: See footnotes at end of schedule
 

 
 
 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
    TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
CONSUMER SEGMENT (2)
            
                 
SKIN CARE
                
US
        
1,582
1,462
8.2%
8.2%
             -
Intl
        
1,885
1,919
(1.8%)
3.9%
(5.7%)
WW
        
3,467
3,381
2.5%
5.7%
(3.2%)
                   
BABY CARE
                
US
        
414
449
(7.8%)
(7.8%)
             -
Intl
        
1,701
1,765
(3.6%)
1.7%
(5.3%)
WW
        
2,115
2,214
(4.5%)
(0.2%)
(4.3%)
                   
ORAL CARE
                
US
        
716
780
(8.2%)
(8.2%)
             -
Intl
        
853
844
1.1%
8.6%
(7.5%)
WW
        
1,569
1,624
(3.4%)
0.5%
(3.9%)
                   
OTC/NUTRITIONALS
              
US
        
2,944
3,061
(3.8%)
(3.8%)
             -
Intl
        
2,686
2,833
(5.2%)
1.9%
(7.1%)
WW
        
5,630
5,894
(4.5%)
(1.1%)
(3.4%)
                   
WOMEN'S HEALTH
              
US
        
578
618
(6.5%)
(6.5%)
             -
Intl
        
1,317
1,293
1.9%
8.4%
(6.5%)
WW
        
1,895
1,911
(0.8%)
3.6%
(4.4%)
                   
WOUND CARE / OTHER
            
US
        
603
567
6.3%
6.3%
             -
Intl
        
524
463
13.2%
19.9%
(6.7%)
WW
        
1,127
1,030
9.4%
12.2%
(2.8%)
                   
TOTAL CONSUMER
              
US
        
6,837
6,937
(1.4%)
(1.4%)
             -
Intl
        
8,966
9,117
(1.7%)
4.7%
(6.4%)
WW
        
15,803
16,054
(1.6%)
2.0%
(3.6%)
 
Note: See footnotes at end of schedule
 

 
 
 
 
 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2)
            
                   
ACIPHEX/PARIET
                
US
        
       158
      140
12.9%
12.9%
             -
Intl
        
       154
      134
14.9%
2.7%
12.2%
WW
        
       312
      274
13.9%
8.0%
5.9%
         
 
 
      
CONCERTA
                
US
        
       279
      208
34.1%
34.1%
             -
Intl
        
       102
        72
41.7%
31.2%
10.5%
WW
        
       381
      280
36.1%
33.4%
2.7%
         
 
 
      
DURAGESIC/FENTANYL TRANSDERMAL
            
US
        
         53
        72
(26.4%)
(26.4%)
             -
Intl
        
       180
      200
(10.0%)
(19.4%)
9.4%
WW
        
       233
      272
(14.3%)
(21.2%)
6.9%
         
 
 
      
LEVAQUIN/FLOXIN
                
US
        
       433
      393
10.2%
10.2%
             -
Intl
        
         19
        18
5.6%
1.7%
3.9%
WW
        
       452
      411
10.0%
9.8%
0.2%
         
 
 
      
PROCRIT/EPREX
                
US
        
       308
      318
(3.1%)
(3.1%)
             -
Intl
        
       268
      242
10.7%
(0.3%)
11.0%
WW
        
       576
      560
2.9%
(1.9%)
4.8%
         
 
 
      
RAZADYNE/REMINYL
              
US
        
           6
        11
(45.5%)
(45.5%)
             -
Intl
        
       104
        91
14.3%
2.0%
12.3%
WW
        
       110
      102
7.8%
(3.2%)
11.0%
         
 
 
      
REMICADE
                
US
        
       758
      672
12.8%
12.8%
             -
US Exports (4)
      
       375
      209
79.4%
79.4%
             -
Intl
        
           5
          5
             -
(0.3%)
0.3%
WW
        
    1,138
      886
28.4%
28.4%
             -
 
Note: See footnotes at end of schedule
 
 
 


            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2)
            
                   
ACIPHEX/PARIET
                
US
        
555
539
3.0%
3.0%
             -
Intl
        
541
619
(12.6%)
(6.7%)
(5.9%)
WW
        
1,096
1,158
(5.4%)
(2.3%)
(3.1%)
         
 
 
      
CONCERTA
                
US
        
986
830
18.8%
18.8%
             -
Intl
        
340
417
(18.5%)
(11.9%)
(6.6%)
WW
        
1,326
1,247
6.3%
8.5%
(2.2%)
         
 
 
      
DURAGESIC/FENTANYL TRANSDERMAL
            
US
        
216
271
(20.3%)
(20.3%)
             -
Intl
        
672
765
(12.2%)
(8.3%)
(3.9%)
WW
        
888
1,036
(14.3%)
(11.4%)
(2.9%)
                   
LEVAQUIN/FLOXIN
                
US
        
1,478
1,510
(2.1%)
(2.1%)
             -
Intl
        
72
81
(11.1%)
1.6%
(12.7%)
WW
        
1,550
1,591
(2.6%)
(2.0%)
(0.6%)
         
 
 
      
PROCRIT/EPREX
                
US
        
1,258
1,332
(5.6%)
(5.6%)
             -
Intl
        
987
1,128
(12.5%)
(7.1%)
(5.4%)
WW
        
2,245
2,460
(8.7%)
(6.2%)
(2.5%)
         
 
        
RAZADYNE/REMINYL
              
US
        
36
134
(73.1%)
(73.1%)
             -
Intl
        
379
407
(6.9%)
(0.5%)
(6.4%)
WW
        
415
541
(23.3%)
(18.5%)
(4.8%)
         
 
        
REMICADE
                
US
        
3,088
2,810
9.9%
9.9%
             -
US Exports (4)
      
1,196
927
29.0%
29.0%
             -
Intl
        
20
11
81.8%
78.8%
3.0%
WW
        
4,304
3,748
14.8%
14.8%
             -
 
Note: See footnotes at end of schedule
 
 
 
 


            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2) (Continued)
            
                   
RISPERDAL/RISPERIDONE
            
US
        
         24
        91
(73.6%)
(73.6%)
             -
Intl
        
       169
      194
(12.9%)
(20.9%)
8.0%
WW
        
       193
      285
(32.3%)
(37.8%)
5.5%
         
 
 
      
RISPERDAL CONSTA
              
US
        
       133
      117
13.7%
13.7%
             -
Intl
        
       266
      202
31.7%
20.6%
         11.1
WW
        
       399
      319
25.1%
18.1%
          7.0
         
 
 
      
TOPAMAX
                
US
        
         89
      576
(84.5%)
(84.5%)
             -
Intl
        
       103
      104
(1.0%)
(11.7%)
10.7%
WW
        
       192
      680
(71.8%)
(73.4%)
1.6%
         
 
 
      
VELCADE
                
US
        
          -
         -
             -
                          -
             -
Intl
        
       281
      208
35.1%
26.5%
8.6%
WW
        
       281
      208
35.1%
26.5%
8.6%
         
 
 
      
OTHER
                  
US
        
       722
      623
15.9%
15.9%
             -
Intl
        
    1,004
      785
27.9%
19.1%
8.8%
WW
        
    1,726
   1,408
22.6%
17.7%
4.9%
         
 
 
      
TOTAL PHARMACEUTICAL
            
US
        
    3,338
   3,430
(2.7%)
(2.7%)
             -
Intl
        
    2,655
   2,255
17.7%
8.0%
9.7%
WW
        
    5,993
   5,685
5.4%
1.6%
3.8%
                   
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
        
                   
PREZISTA
                
US
        
88
50
76.0%
76.0%
             -
Intl
        
91
43
111.6%
98.7%
12.9%
WW
        
179
93
92.5%
86.5%
6.0%
                   
INVEGA
                  
US
        
72
70
2.9%
2.9%
             -
Intl
        
34
25
36.0%
23.8%
12.2%
WW
        
106
95
11.6%
8.4%
3.2%
 
Note: See footnotes at end of schedule
 
 
 
 
 


            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
PHARMACEUTICAL SEGMENT  (2) (Continued)
            
                   
RISPERDAL/RISPERIDONE
            
US
        
247
1,287
(80.8%)
(80.8%)
             -
Intl
        
652
839
(22.3%)
(21.2%)
(1.1%)
WW
        
899
2,126
(57.7%)
(57.3%)
(0.4%)
         
 
 
      
RISPERDAL CONSTA
              
US
        
519
456
13.8%
13.8%
             -
Intl
        
906
853
6.2%
14.5%
(8.3%)
WW
        
1,425
1,309
8.9%
14.3%
(5.4%)
         
 
 
      
TOPAMAX
                
US
        
731
2,250
(67.5%)
(67.5%)
             -
Intl
        
420
481
(12.7%)
(5.3%)
(7.4%)
WW
        
1,151
2,731
(57.9%)
(56.6%)
(1.3%)
         
 
 
      
VELCADE
                
US
        
             -
4
(100.0%)
(100.0%)
             -
Intl
        
933
783
19.2%
26.7%
(7.5%)
WW
        
933
787
18.6%
26.0%
(7.4%)
         
 
 
      
OTHER
                  
US
        
2,731
2,481
10.1%
10.1%
             -
Intl
        
3,557
3,352
6.1%
11.4%
(5.3%)
WW
        
6,288
5,833
7.8%
10.8%
(3.0%)
         
 
 
      
TOTAL PHARMACEUTICAL
            
US
        
13,041
14,831
(12.1%)
(12.1%)
             -
Intl
        
9,479
9,736
(2.6%)
3.0%
(5.6%)
WW
        
22,520
24,567
(8.3%)
(6.1%)
(2.2%)
         
 
 
      
MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
                   
PREZISTA
                
US
        
303
159
90.6%
90.6%
             -
Intl
        
289
175
65.1%
77.0%
(11.9%)
WW
        
592
334
77.2%
83.4%
(6.2%)
                   
INVEGA
                  
US
        
266
262
1.5%
1.5%
             -
Intl
        
127
64
98.4%
111.7%
(13.3%)
WW
        
393
326
20.6%
23.2%
(2.6%)
 
Note: See footnotes at end of schedule
 
 
 
 
 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
FOURTH QUARTER
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
MEDICAL DEVICES AND DIAGNOSTICS  (2) (3)
            
 
CORDIS (6)
                
US
        
       240
      236
1.7%
1.7%
             -
Intl
        
       457
      448
2.0%
(5.8%)
7.8%
WW
        
       697
      684
1.9%
(3.2%)
5.1%
         
 
 
      
DEPUY
                  
US
        
       828
      744
11.3%
11.3%
             -
Intl
        
       645
      546
18.1%
8.3%
9.8%
WW
        
    1,473
   1,290
14.2%
10.1%
4.1%
                   
DIABETES CARE
                
US
        
       313
      275
13.8%
13.8%
             -
Intl
        
       342
      304
12.5%
2.9%
9.6%
WW
        
       655
      579
13.1%
8.0%
5.1%
         
 
 
      
ETHICON
                
US
        
       458
      363
26.2%
26.2%
             -
Intl
        
       651
      555
17.3%
7.5%
9.8%
WW
        
    1,109
      918
20.8%
14.8%
6.0%
         
 
 
      
ETHICON ENDO-SURGERY
            
US
        
       532
      515
3.3%
3.3%
             -
Intl
        
       724
      602
20.3%
10.5%
9.8%
WW
        
    1,256
   1,117
12.4%
7.0%
5.4%
         
 
 
      
ORTHO-CLINICAL DIAGNOSTICS
            
US
        
       258
      248
4.0%
4.0%
             -
Intl
        
       243
      204
19.1%
10.6%
8.5%
WW
        
       501
      452
10.8%
6.9%
3.9%
         
 
 
      
VISION CARE
                
US
        
       188
      201
(6.5%)
(6.5%)
             -
Intl
        
       430
      401
7.2%
(0.7%)
7.9%
WW
        
       618
      602
2.7%
(2.6%)
5.3%
         
 
 
      
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
          
US
        
    2,817
   2,582
9.1%
9.1%
             -
Intl
        
    3,492
   3,060
14.1%
4.9%
9.2%
WW
        
    6,309
   5,642
11.8%
6.8%
5.0%
 
Note: See footnotes at end of schedule
 
 
 
 

            REPORTED SALES vs. PRIOR PERIOD
            $MM
                   
         
TWELVE MONTHS
             
% Change
         
2009
2008
Reported
Operational (1)
Currency
                   
MEDICAL DEVICES AND DIAGNOSTICS  (2) (3)
            
 
CORDIS (6)
                
US
        
971
1,165
(16.7%)
(16.7%)
             -
Intl
        
1,708
1,823
(6.3%)
(4.4%)
(1.9%)
WW
        
2,679
2,988
(10.3%)
(9.1%)
(1.2%)
                   
DEPUY
                  
US
        
3,096
2,873
7.8%
7.8%
             -
Intl
        
2,276
2,263
0.6%
7.2%
(6.6%)
WW
        
5,372
5,136
4.6%
7.5%
(2.9%)
                   
DIABETES CARE
                
US
        
1,221
1,265
(3.5%)
(3.5%)
             -
Intl
        
1,219
1,270
(4.0%)
0.8%
(4.8%)
WW
        
2,440
2,535
(3.7%)
(1.3%)
(2.4%)
                   
ETHICON
                
US
        
1,754
1,450
21.0%
21.0%
             -
Intl
        
2,368
2,390
(0.9%)
4.5%
(5.4%)
WW
        
4,122
3,840
7.3%
10.7%
(3.4%)
                   
ETHICON ENDO-SURGERY
            
US
        
1,974
1,901
3.8%
3.8%
             -
Intl
        
2,518
2,385
5.6%
10.6%
(5.0%)
WW
        
4,492
4,286
4.8%
7.6%
(2.8%)
                   
ORTHO-CLINICAL DIAGNOSTICS
            
US
        
1,104
997
10.7%
10.7%
             -
Intl
        
859
844
1.8%
6.3%
(4.5%)
WW
        
1,963
1,841
6.6%
8.6%
(2.0%)
                   
VISION CARE
                
US
        
891
890
0.1%
0.1%
             -
Intl
        
1,615
1,610
0.3%
                      -
0.3%
WW
        
2,506
2,500
0.2%
0.1%
0.1%
                   
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
          
US
        
11,011
10,541
4.5%
4.5%
             -
Intl
        
12,563
12,585
(0.2%)
4.0%
(4.2%)
WW
        
23,574
23,126
1.9%
4.2%
(2.3%)
 
(1) Operational growth excludes the effect of currency.
(2) Select areas (unaudited).
(3) Prior year amounts have been reclassified to conform with current presentation.
(4) Reported in U.S. sales.
(5) Included in Other.
(6) Includes sales of Drug-Eluting Stents for Q4 2009 of $56, $167 and $223MM Domestic, International and Worldwide, respectively.
      Includes sales of Drug-Eluting Stents for Q4 2008 of $70, $202 and $272MM Domestic, International and Worldwide, respectively.
      Includes sales of Drug-Eluting Stents for December YTD 2009 of $245, $674 and $919MM Domestic, International and Worldwide,
        respectively.
      Includes sales of Drug-Eluting Stents for December YTD 2008 of $503, $852 and $1,355MM Domestic, International and Worldwide,
        respectively.